Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Mar 18;78(7):568-577.
doi: 10.1093/ajhp/zxaa426.

Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

Nathaniel J Rhodes  1   2   3 , Atheer Dairem  1 , William J Moore  1 , Anooj Shah  1   2 , Michael J Postelnick  1 , Melissa E Badowski  4 , Sarah M Michienzi  4 , Jaime L Borkowski  5 , Radhika S Polisetty  2   6 , Karen Fong  7 , Emily S Spivak  8 , James R Beardsley  9   10 , Cory M Hale  11 , Andrea M Pallotta  12 , Pavithra Srinivas  12 , Lucas T Schulz  13
Affiliations
Multicenter Study

Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

Nathaniel J Rhodes et al. Am J Health Syst Pharm. .

Abstract

Key points: In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients.

Purpose: There are currently no FDA-approved medications for the treatment of coronavirus disease 2019 (COVID-19). At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period.

Methods: We conducted a noninterventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19-targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs).

Results: A total of 352 patients treated for COVID-19 at 15 US hospitals From April 18 to May 8, 2020, were included in the study. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies used included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 antagonists (9%). Five patients (7.5%) were receiving combination therapy. The rate of use of COVID-19-directed drug therapy was higher in patients with vs patients without a history of asthma (14.9% vs 7%, P = 0.037) and in patients enrolled in clinical trials (26.9% vs 3.2%, P < 0.001). Among those receiving drug therapy, 8 patients (12%) experienced an ADR, and ADRs were recognized at a higher rate in patients enrolled in clinical trials (62.5% vs 22%; odds ratio, 5.9; P = 0.028).

Conclusion: While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy, including those enrolled in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 treatments.

Keywords: COVID-19; SARS-CoV-2; adverse drug reaction; medication safety; observational study; supportive care.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Timeline of events during early months of COVID-19 pandemic in the United States. Case data are those reported by Centers for Disease Control and Prevention as of the time of writing. EUA indicates emergency use authorization; FDA, Food and Drug Administration; NIH, National Institutes of Health.
See this image and copyright information in PMC

Update of

References

    1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): coronavirus disease 2019 basics. Accessed May 31, 2020. https://www.cdc.gov/coronavirus/2019-ncov/faq.html#Coronavirus-Disease-2...
    1. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):ofaa105. - PMC - PubMed
    1. Zhai MZ, Lye CT, Kesselheim AS. Need for transparency and reliable evidence in emergency use authorizations for coronavirus disease 2019 (COVID-19) therapies. Published online May 19, 2020. JAMA Intern Med. doi: 10.1001/jamainternmed.2020.2402 - DOI - PubMed
    1. COVID-19 Treatment Guidelines Panel, National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed May 31, 2020. https://www.covid19treatmentguidelines.nih.gov - PubMed
    1. Food and Drug Administration. FDA drug safety communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Published April 24, 2020. Accessed May 31, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-agai...

Publication types

MeSH terms